Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPROF
āļāļ·āđāļāļāļĢāļīāļĐāļąāļProfound Medical Corp
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 24, 2014
āļāļĩāļāļĩāđāļMenawat (Arun Swarup)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļSep 24
āļāļĩāđāļāļĒāļđāđ2400 Skymark Ave Unit 6
āđāļĄāļ·āļāļMISSISSAUGA
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđL4W 5K5
āđāļāļĢāļĻāļąāļāļāđ16474761350
āđāļ§āđāļāđāļāļāđhttps://profoundmedical.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPROF
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 24, 2014
āļāļĩāļāļĩāđāļMenawat (Arun Swarup)
Dr. Mathieu Burtnyk
Chief Technology Officer
Mr. Richard (Rich) Fabian
Mr. Richard (Rich) Fabian
President, Chief Executive Officer
President, Chief Executive Officer
Dr. Arun Swarup Menawat, Ph.D.
Dr. Arun Swarup Menawat, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
Mr. Brian Ellacott
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
Dr. Arthur L. Rosenthal, Ph.D.
Dr. Arthur L. Rosenthal, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Rashed Dewan
Chief Financial Officer
Mr. Stephen Kilmer
Investor Relations
Ms. Murielle Lortie, CPA
Non-Executive Independent Director
Non-Executive Independent Director
Dr. Cynthia Lavoie, Ph.D.
Dr. Cynthia Lavoie, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Kris Shah
Non-Executive Independent Director
Non-Executive Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Mathieu Burtnyk
Chief Technology Officer
Mr. Richard (Rich) Fabian
Mr. Richard (Rich) Fabian
President, Chief Executive Officer
President, Chief Executive Officer
Dr. Arun Swarup Menawat, Ph.D.
Dr. Arun Swarup Menawat, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
Mr. Brian Ellacott
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
Dr. Arthur L. Rosenthal, Ph.D.
Dr. Arthur L. Rosenthal, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Rashed Dewan
Chief Financial Officer